Reckitt Benckiser Group (OTCMKTS:RBGLY) Downgraded by Sanford C. Bernstein to Hold

Sanford C. Bernstein lowered shares of Reckitt Benckiser Group (OTCMKTS:RBGLY) from a strong-buy rating to a hold rating in a research report sent to investors on Monday, Zacks.com reports.

Several other research firms also recently issued reports on RBGLY. Citigroup upgraded Reckitt Benckiser Group to a “strong-buy” rating in a report on Tuesday, October 1st. Barclays upgraded Reckitt Benckiser Group to a “strong-buy” rating in a report on Friday, October 4th. JPMorgan Chase & Co. lowered Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 29th. Finally, UBS Group upgraded shares of Reckitt Benckiser Group to a “strong-buy” rating in a research note on Wednesday, September 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Reckitt Benckiser Group currently has a consensus rating of “Moderate Buy”.

Reckitt Benckiser Group Stock Performance

Shares of OTCMKTS:RBGLY opened at $12.89 on Monday. The company has a current ratio of 0.69, a quick ratio of 0.47 and a debt-to-equity ratio of 0.97. The stock has a fifty day moving average of $12.22 and a 200-day moving average of $11.56. Reckitt Benckiser Group has a one year low of $10.24 and a one year high of $15.03.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.